课题基金 / 基金详情

Role of Altered Nutrient Metabolism in Pancreatic Cancer

Role of Altered Nutrient Metabolism in Pancreatic Cancer
营养代谢改变在胰腺癌中的作用
批准号:
10598613
负责人:
Nada Y. Kalaany
金额:
$51.41万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-04-01 至 2027-03-31
关键词:
AcetylationAddressAdultAffectAminesAreaArginineAutomobile DrivingBindingBiological AssayBiologyCancer EtiologyCancer PatientCell SurvivalCell physiologyCellsCessation of lifeChIP-seqChargeChromatinChromatin StructureCultured CellsDataDatabasesDependenceDiagnosisDoseDoxycyclineDuctal Epithelial CellEnhancersEnzyme InhibitionEnzymesEpigenetic ProcessExtinctionGene ExpressionGene Expression ProfileGeneticGenetic TranscriptionGenetically Engineered MouseGlutamineGoalsGrowthHistone H3HistonesHomeostasisHumanIn VitroIncidenceInfusion proceduresIntercellular FluidInterventionInvestigationKRAS2 geneKnock-outLabelLysineMaintenanceMalignant NeoplasmsMalignant neoplasm of pancreasMediatingMetabolicMetabolic PathwayMetabolismMusNatureNitrogenNormal CellNormal tissue morphologyNucleic AcidsNucleotidesOncogenicOrnithineOrnithine DecarboxylaseOrnithine-oxo-acid aminotransferasePancreasPancreatic Ductal AdenocarcinomaPancreatic ductPathway interactionsPharmaceutical PreparationsPolyaminesProductionPrognosisProteinsPutrescineRiskRisk FactorsRoleSourceSpermidineSpermineSurvival RateTherapeuticTissuesToxic effectTranscriptional ActivationTranslationsTransplantationTransposaseWithdrawalWorkarginasecell growthchromatin modificationeffective therapyexperimental studyhigh riskin vivoinfancyknock-downmRNA Translationmouse modelneoplastic cellnovelnovel therapeutic interventionnutrient metabolismpancreatic cancer patientspancreatic ductal adenocarcinoma cellpancreatic ductal adenocarcinoma modelpancreatic neoplasmpharmacologicside effectstemsuccesstherapy resistanttranscription factortranscriptome sequencingtumortumor growthtumorigenic

项目摘要

项目成果

Nada Y. Kalaany的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/摘要 胰腺导管腺癌(PDAC)是一种高度致命的恶性肿瘤,是胰腺癌的主要形式。 癌随着发病率的上升,它目前已成为美国癌症死亡的第三大原因。 尽管最近在了解其生物学,遗传学和风险因素方面取得了进展,但PDAC仍然保持 预后极差,5年生存率仅为10%。这主要是由于其诊断较晚, 攻击性和对治疗的抵抗力。因此,迫切需要新的治疗方法。 靶向PDAC中的代谢改变已经是十多年来广泛研究的领域。一 然而,对于大多数抗肿瘤代谢策略来说,主要障碍是毒副作用的高风险, 代谢途径在维持正常组织稳态中的重要作用。这确实是 针对癌症中的多胺的案例。多胺是一种小的、带高度正电荷的分子 参与细胞生长和存活的多个基本过程,包括核酸的合成, 染色质结构、基因转录和mRNA翻译的修饰。多胺水平是 在包括PDAC在内的许多癌症中显著增加。以前的抗肿瘤策略集中在 多胺合成限速酶鸟氨酸脱羧酶(ODC 1)的药理学抑制 但收效甚微,部分原因是在较高的药物剂量下有损害正常组织的风险。该项目确定 目的是验证胰腺癌在体外培养细胞和小鼠体内对 合成多胺前体鸟氨酸的非常规方法,特别是由谷氨酰胺通过 鸟氨酸氨基转移酶(OAT);这与其在大多数成人正常组织中由精氨酸合成相比 通过精氨酸酶(ARG)活性。它还旨在确定调解这一进程的潜在关键角色, 通过KRAS代谢途径,PDAC中的主要致癌驱动因素,并表征下游效应 与正常胰腺相比,多胺对PDAC细胞转录激活和基因表达的影响 细胞PDAC而非正常组织对谷氨酰胺从头合成鸟氨酸的高度依赖性 为治疗胰腺癌患者提供了一个有吸引力的治疗窗口,具有最小的毒性。
英文摘要
PROJECT SUMMARY/ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy and is the major form of pancreatic cancer. With an incidence on the rise, it currently ranks as the third leading cause of cancer death in the US. Despite recent advances in the understanding of its biology, genetics and risk factors, PDAC has maintained extremely poor prognosis, with a 5-year survival rate of only 10%. This mainly stems from its late diagnosis, aggressive nature and resistance to therapies. Thus, novel therapeutic approaches are urgently needed. Targeting altered metabolism in PDAC has been an area of extensive investigation for over a decade now. A major hurdle however, for most anti-tumor metabolic strategies, is the high risk of toxic side effects, given the essential roles of metabolic pathways in the maintenance of normal tissue homeostasis. This has indeed been the case for targeting polyamines in cancers. Polyamines are small, highly positively charged molecules involved in multiple fundamental processes of cell growth and survival, including the synthesis of nucleic acids, modifications of chromatin structure, gene transcription and mRNA translation. Polyamine levels are significantly increased in many cancers, including PDAC. Prior anti-tumor strategies focused on pharmacological inhibition of the rate-limiting enzyme of polyamine synthesis, ornithine decarboxylase (ODC1) with little success, partially due to risk of harming normal tissues at higher drug doses. This project identifies and aims at validating a dependency of pancreatic cancer, both in cultured cells in vitro and in mice in vivo, on an unconventional way for the synthesis of the polyamine precursor ornithine, specifically from glutamine via ornithine aminotransferase (OAT); this is compared to its synthesis in most adult normal tissues from arginine via arginase (ARG) activity. It also aims at identifying potential key players mediating the induction of this metabolic pathway by KRAS, the main oncogenic driver in PDAC, and to characterize the downstream effects of polyamines on transcriptional activation and gene expression in PDAC cells compared to normal pancreatic cells. The high dependency of PDAC, but not normal tissues on de novo ornithine synthesis from glutamine provides an attractive therapeutic window for treating pancreatic cancer patients with minimal toxicity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of Insulin Receptor Substrates in Kras-driven lung cancer
  • 批准号:
    10163809
  • 项目类别:
  • 资助金额:
    $40.49万
  • 财政年份:
    2017
  • 负责人:
    Nada Y. Kalaany
  • 依托单位:
Role of Insulin Receptor Substrates in Kras-driven lung cancer
  • 批准号:
    9895645
  • 项目类别:
  • 资助金额:
    $40.49万
  • 财政年份:
    2017
  • 负责人:
    Nada Y. Kalaany
  • 依托单位:
Role of Insulin Receptor Substrates in Kras-driven lung cancer
  • 批准号:
    9383140
  • 项目类别:
  • 资助金额:
    $40.49万
  • 财政年份:
    2017
  • 负责人:
    Nada Y. Kalaany
  • 依托单位:
海外基金